{
    "brief_title": "Metronomic PLD in Patients With Primary Endocrine Resistant ABC",
    "phase": "Phase 2",
    "drugs": "['Pegylated Liposomal Doxorubicin']",
    "drugs_list": [
        "Pegylated Liposomal Doxorubicin"
    ],
    "diseases": "['Advanced Breast Cancer']",
    "diseases_list": [
        "Advanced Breast Cancer"
    ],
    "enrollment": "46.0",
    "inclusion_criteria": "inclusion criteria: \n\n Females with age between 18 and 75 years old \n\n ECOG: 0\uff5e2 \n\n Life expectancy longer than 3 months \n\n Histological proven unresectable recurrent or metastatic HR positive/HER2 negative breast cancer \n\n Primary endocrine resistance is defined as: a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC, while on ET \n\n At least one measurable disease according to RECIST 1.1(except for bone metastasis only) \n\n LVEF \u2265 55% \n\n No radiation therapy within 4 weeks prior to enrollment \n\n Normal function of major organs: Hb \u2265 90 g/L (no blood transfusion within 14 days) ;ANC \u22651.5\u00d7109 /L\uff1bPLT \u226575\u00d7109 /L\uff1bTBIL\u22641. 5\u00d7ULN; ALT\u3001 AST\u2264 3\u00d7ULN\uff08ALT\u3001 AST\u2264 5\u00d7ULN with hepatic metastases\uff09; serum Cr \u2264 1\u00d7ULN \n\n Be willing to participate in the study, sign informed consent and cooperate with the follow-up \n\n ",
    "exclusion_criteria": ": \n\n Previous accumulated or equivalent dose of doxorubicin \u2265300mg/m2 \n\n Intervals of anthracycline-based adjuvant chemotherapy \u22641 year (time between anthracycline-based adjuvant or neoadjuvant chemotherapy and disease relapse) \n\n Patients with symptomatic central nervous system metastases. Except for patients with stable and asymptomatic brain metastases for at least 8 weeks and no need for glucocorticoids or mannitol treatment before the trial and at least one measurable lesion outside the brain. Radiotherapy for brain metastases should be completed at least 4 weeks before the registration \n\n Pregnant or lactating women and gestational age women who are unable to use effective contraception \n\n Treatment with investigational products within 4 weeks before the study \n\n Severe cardiopulmonary insufficiency, severe hepatic and renal dysfunction \n\n Severe or uncontrolled infection \n\n Psychiatric drugs abuse and unable to withdrawal or mental disorders \n\n Other malignancies, except for cured skin basal cell carcinoma and cervical intraepithelial neoplasia.",
    "brief_summary": "Metronomic PLD in Patients with Primary Endocrine Resistant ABC",
    "NCT_ID": "NCT03071926"
}